NCT04633889

Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 320 (actual)
• Sponsor: Brigham and Women's Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Multiple lines of evidence support a central role of iron in causing acute kidney injury (AKI), including the finding that prophylactic administration of iron chelators attenuates AKI in animal models. Patients undergoing cardiac surgery may be particularly susceptible to iron-mediated kidney injury due to the profound hemolysis that often occurs from cardiopulmonary bypass. The investigators will test in a phase 2, randomized, double-blind, placebo-controlled trial whether prophylactic administration of deferoxamine decreases the incidence of AKI following cardiac surgery.

Conditions

• Acute Kidney Injury

Interventions

Type	Name	Description
DRUG	Deferoxamine	Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours
DRUG	Normal saline	Normal saline (240mL) intravenous infusion over 12 hours

Timeline

• Start date: 2021-04-13
• Primary completion: 2024-08-26
• Completion: 2026-03-01
• First posted: 2020-11-18
• Last updated: 2026-01-26
• Results posted: 2026-01-26

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study